Aug 2026· Archives of Medical Research· Vol 57 8, pp.
103506
· 0 citations· 103 references
Medicine
TL;DR
A comprehensive clinical workflow is outlined that integrates deep phenotyping, genomic variant identification, and functional validation with multi-omics approaches to enhance diagnostic accuracy in RDs and improve understanding of RDs within the framework of precision medicine.
Abstract
One of the main challenges in the field of rare diseases (RDs) remains the persistent lack of timely and accurate diagnoses. Currently, it is estimated that over half of patients remain undiagnosed. The recent development of high-throughput omics technologies, such as genomics, transcriptomics, epigenomics, proteomics, and metabolomics, is transforming the diagnosis and research of rare genetic diseases. These technologies allow for a deeper understanding of the underlying molecular mechanisms and greatly improve diagnostic accuracy. This review outlines a comprehensive clinical workflow that integrates deep phenotyping, genomic variant identification, and functional validation with multi-omics approaches to enhance diagnostic accuracy in RDs. We detail the key methodologies, bioinformatics tools, and developmental processes used in omics, focusing on their roles in identifying and prioritizing candidate variants, interpreting variants of uncertain significance, and generating clinically relevant information. Furthermore, we highlight the importance of both targeted and non-targeted functional validation strategies, which provide essential evidence of pathogenicity. The integration of multi-omics approaches will improve our understanding of RDs, enhance diagnostic accuracy in clinical settings, and lay the foundation for future therapeutic development within the framework of precision medicine.
Despite the introduction of genome sequencing (GS) for rare disease diagnostics, a genetic cause is not identified in most patients. Here, we explored the potential of proteomics to improve the diagnostic yield in 424 patients with rare diseases from the 100,000 Genomes Project (100kGP) without a genetic diagnosis. Ser...
J. Carrasco-Zanini, J. Andrade, M. Pietzner et al.· Science Translational Medici...· 0 citations
Recent technological advances and applications of multi-omics in kidney diseases are critically reviewed, with particular attention to biomarker discovery and clinical translation, and the challenges and future directions of multi-omics integration and its application in precision medicine are discussed.
INTRODUCTION
As precision medicine increasingly relies on genetic information, the development of reliable genomic point-of-care tests (POCTs) is essential. However, the number of technologies that have reached true clinical usability is limited. There is a growing need for POCTs that enable rapid, accurate analysis of...
S. Haston, J. Elgey, O. Ewedairo et al.· Pharmacogenomics (London)· 0 citations
Whole-genome sequencing is increasingly emerging as a first-line genomic strategy for pediatric rare diseases, while complementary technologies, expert phenotyping, and iterative data interpretation remain essential for comprehensive and accurate diagnosis and equitable access to genomic medicine.
Natàlia Caelles-Gramunt, J. Pijuan· Children· 1 citation
Transcriptomics and metabolomics occupy mechanistically complementary positions in the molecular hierarchy of disease: gene expression characterizes upstream regulatory dysregulation, while metabolomics captures the downstream biochemical consequence at the functional endpoint of that cascade. Applied alone, each yield...
Kashyap N. Thummar, Sneha M. Nair, Foram K. Ravat et al.· Critical reviews in analytic...· 0 citations
Allergic and inflammatory respiratory conditions are complex and heterogeneous diseases affecting a large portion of the population. Although omics technologies have enabled the identification of potential biomarkers, single-omics-based approaches often fail to capture the full complexity of these disorders. Multi-...
Silvia Garcés Rigol, N. Contreras, R. Nuñez et al.· Frontiers in Bioinformatics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.